详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Editorial: The diversified role of mitochondria in cancer

3| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neuroscience, Baylor College of Medicine, Houston, TX, United States [2]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [3]Division of Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States [4]First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [5]Cellphire Therapeutics Inc., Rockville, MD, United States [6]Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, United States [7]Center of Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China [8]Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, Chengdu, China

出处：

DOI：

ISSN：

关键词： mitochondrial dysfunction cancer metabolism immune evasion programmed cell death biomarkers personalized therapy tumor microenvironment mitochondrial-targeted therapies

基金：

基金编号： 81802504 2023YFH0010

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 3 区生物学

小类 | 3 区遗传学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q2 GENETICS & HEREDITY

影响因子： 2.8 最新[2023版] 3.3 最新五年平均 2.8 出版当年[2023版] 0 出版当年五年平均 2.8 出版前一年[2023版]

第一作者：

第一作者机构： [1]Department of Neuroscience, Baylor College of Medicine, Houston, TX, United States

共同第一作者：

通讯作者：

通讯机构： [7]Center of Critical Care Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China [8]Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, Chengdu, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells [2]Editorial: Liver diseases and programmed cell death [3]Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. [4]CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. [5]SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade [6]Cancer metabolism and tumor microenvironment: fostering each other? [7]Cancer metabolism and tumor microenvironment: fostering each other? [8]Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment [9]Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. [10]Long noncoding RNA H19: functions and mechanisms in regulating programmed cell death in cancer